Seroatlas · Human Serome Atlas

ACSL3

Fatty acid CoA ligase Acsl3

Also known as: ACS3, ACSL3_HUMAN, FACL3, PRO2194

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O95573
Gene
ACSL3
Ensembl
ENSG00000123983
Chromosome
2
Canonical length
720 aa
Protein class
Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Nucleoli,Nucleoli rim,Lipid droplets

OverviewNCBI Gene

The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme is highly expressed in brain, and preferentially utilizes myristate, arachidonate, and eicosapentaenoate as substrates. The amino acid sequence of this isozyme is 92% identical to that of rat homolog. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

720 residues, UniProt reviewed canonical sequence.

>O95573|ACSL3
     1  MNNHVSSKPS TMKLKHTINP ILLYFIHFLI SLYTILTYIP FYFFSESRQE KSNRIKAKPV
    61  NSKPDSAYRS VNSLDGLASV LYPGCDTLDK VFTYAKNKFK NKRLLGTREV LNEEDEVQPN
   121  GKIFKKVILG QYNWLSYEDV FVRAFNFGNG LQMLGQKPKT NIAIFCETRA EWMIAAQACF
   181  MYNFQLVTLY ATLGGPAIVH ALNETEVTNI ITSKELLQTK LKDIVSLVPR LRHIITVDGK
   241  PPTWSEFPKG IIVHTMAAVE ALGAKASMEN QPHSKPLPSD IAVIMYTSGS TGLPKGVMIS
   301  HSNIIAGITG MAERIPELGE EDVYIGYLPL AHVLELSAEL VCLSHGCRIG YSSPQTLADQ
   361  SSKIKKGSKG DTSMLKPTLM AAVPEIMDRI YKNVMNKVSE MSSFQRNLFI LAYNYKMEQI
   421  SKGRNTPLCD SFVFRKVRSL LGGNIRLLLC GGAPLSATTQ RFMNICFCCP VGQGYGLTES
   481  AGAGTISEVW DYNTGRVGAP LVCCEIKLKN WEEGGYFNTD KPHPRGEILI GGQSVTMGYY
   541  KNEAKTKADF FEDENGQRWL CTGDIGEFEP DGCLKIIDRK KDLVKLQAGE YVSLGKVEAA
   601  LKNLPLVDNI CAYANSYHSY VIGFVVPNQK ELTELARKKG LKGTWEELCN SCEMENEVLK
   661  VLSEAAISAS LEKFEIPVKI RLSPEPWTPE TGLVTDAFKL KRKELKTHYQ ADIERMYGRK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ACSL3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.24
Highest tissue expression
162 nTPM

Expression across tissuesHPA

Tissue

  • parathyroid gland: 162 nTPM
  • breast: 85 nTPM
  • prostate: 62 nTPM
  • stomach: 48 nTPM
  • salivary gland: 38 nTPM
  • esophagus: 34 nTPM

Single-cell type

  • neutrophils: 778 nCPM
  • prostatic glandular cells: 593 nCPM
  • retinal horizontal cells: 533 nCPM
  • retinal ganglion cells: 421 nCPM
  • monocytes: 414 nCPM
  • urothelial cells: 382 nCPM

Immune cell

  • plasmacytoid DC: 21 nTPM
  • eosinophil: 20 nTPM
  • gdT-cell: 18 nTPM
  • MAIT T-cell: 18 nTPM
  • total PBMC: 18 nTPM
  • non-classical monocyte: 17 nTPM

Brain region

  • thalamus: 81 nTPM
  • spinal cord: 65 nTPM
  • hypothalamus: 63 nTPM
  • midbrain: 62 nTPM
  • cerebral cortex: 60 nTPM
  • white matter: 58 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.55
gnomAD pLI
0
gnomAD missense Z
2.01
DepMap mean gene effect
-0.34
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ACSL3 as an antibody target. Whether an autoantibody or antibody against ACSL3 could matter depends on whether native ACSL3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ACSL3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ACSL3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ACSL3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...